Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug:43 Suppl 1:87-95.
doi: 10.1111/liv.15417. Epub 2023 Apr 5.

Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity

Armando A Roca Suarez  1   2 , Enkhtuul Batbold  3 , Birke Bartosch  1   2 , Naranjargal Dashdorj  3   4 , Barbara Testoni  1   2 , Fabien Zoulim  1   2   5
Affiliations
Review

Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity

Armando A Roca Suarez et al. Liver Int. 2023 Aug.

Abstract

Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co-infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono-infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV-specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG-IFN-λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti-HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.

Keywords: HBV; HBsAg; HDV; antivirals; combination therapy.

PubMed Disclaimer

References

REFERENCES

    1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet Lond Engl. 2011;378(9785):73-85. doi:10.1016/S0140-6736(10)61931-9
    1. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32(3):228-236. doi:10.1055/s-0032-1323628
    1. Yurdaydın C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17(11):749-756. doi:10.1111/j.1365-2893.2010.01353.x
    1. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med. 2014;4(11):a021550. doi:10.1101/cshperspect.a021550
    1. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73(3):533-539. doi:10.1016/j.jhep.2020.02.030

Publication types

MeSH terms

Substances

LinkOut - more resources